Inhibrx Reports Third Quarter 2026 Financial Results
PR Newswire•13/11/2026•16:02 ET
0
Key Highlights
- ➤Cash and equivalents reached $199.5 million as of September 30, 2026
- ➤Q3 net loss widened to $38.7 million, or $2.46 per share
- ➤Q3 license revenue totaled $2.0 million from Pfizer agreement
- ➤Q3 R&D expense fell to $26.0 million from $28.5 million
- ➤Phase 2 HexAgon expansion adds approximately 50 HPV-positive HNSCC patients
Inhibrx Reports Third Quarter 2026 Financial Results PR Newswire
SAN DIEGO, Nov. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.
Get started
Create a free account to read the full story.